Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 3/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23064666 | 0.90 | CYP11B1 (0.42) | TAS2R14HTR7TDO2IDO2IDO1 | |
| SCHEMBL23958242 | 0.88 | TDO2 (0.45) | HTR7TDO2IDO2POLBIDO1 | |
| SCHEMBL30025705 | 0.88 | TDO2 (0.45) | HTR7TDO2IDO2POLBIDO1 | |
| SCHEMBL23958214 | 0.85 | TDO2 (0.42) | HTR7TDO2IDO2POLBIDO1 | |
| SCHEMBL24110953 | 0.85 | TDO2 (0.42) | HTR7TDO2IDO2POLBIDO1 | |
| SCHEMBL23958155 | 0.85 | POLB (0.46) | HTR7TDO2IDO2POLBIDO1 | |
| SCHEMBL24110949 | 0.84 | HTR7 (0.44) | HTR7TDO2IDO2POLBPIK3CG | |
| SCHEMBL23045334 | 0.83 | TDO2 (0.50) | HTR7TDO2IDO2POLBIDO1 | |
| SCHEMBL29623155 | 0.83 | TDO2 (0.50) | HTR7TDO2IDO2POLBIDO1 | |
| SCHEMBL23958265 | 0.83 | PIK3CD (0.46) | TDO2IDO2POLBIDO1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | CRKL, CLIC4, CLIC1 | TAS2R14 1861/4885HTR7 1211/4885TDO2 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.